The global fertility services market size is expected to reach USD 36 billion with a CAGR of 8.5% by 2023. Global male infertility market size is expected to reach USD 5.1 billion by 2026 at a CAGR of 5.3%. The global market for femtech (or female-focused technology) is expected to grow to USD $50 billion by 2025.
Picture Credit : Indian Express
Some interesting life science startups companies in this arena are:
Androvia Lifesciences (New York, USA) cutting-edge technology, the Cap-Score™ Assay, is designed to help couples make informed decisions about their fertility. Androvia’s test is the only test capable of helping to determine if the sperm is able to fertilize an egg. Specifically, this laboratory-developed test evaluates capacitation, the physiological cascade undergone by sperm in the female reproductive tract that enables the sperm to fertilize an egg.
Sandstone Diagnostics (Pleasanton, CA) has commercialized its CentriFluidic technology with the Trak Male Fertility Testing System – an FDA approved at-home consumer device that can be mass produced and marketed to the millions of people trying to start their family.
Legacy (Geneva, Switzerland/Boston, USA) is a Harvard-incubated company, provides mail-order service for freezing sperm. It has just raised a fresh, $3.5 million in funding from Bill Maris’s San Diego-based venture firm, Section 32, along with Y Combinator and Bain Capital Ventures, which led a $1.5 million seed round for the Boston startup last year.
Future Fertility (Toronto, Canada) has developed the first Artificial Intelligence software analysis tool to non-invasively evaluate oocytes (eggs), creating the only objective classification and prediction tool for an oocyte.
Mojo Fertility (Lyon, France) is deploying AI and robotics to provide high quality fertility treatment quicker, cheaper and more accurate. Mojo Assess AI-assisted semen analysis platform uses intelligent microscope to make analysis quicker, cheaper and better quality than current manual processes. It recently raised €1.7 million (~$1.8M) seed round of funding led by Nordic seed fund Inventure. The other participants were Doberman and Privilege Ventures and angel investors including Josefin Landgard (founder and ex-CEO of Kry) and Hampus Jakobsson (venture partner at BlueYard, BA in Clue & Kind.app).
Halotech DNA (Madrid, Spain) is a leading biotechnology company dedicated to research, development and marketing of solutions in the field of fertility. Halosperm® is an in vitro diagnostic kit that allows the measurement of DNA fragmentation in a fast, easy, and reproducible manner, without the need for complex laboratory equipment. Halosperm® allows for an improved evaluation of sperm quality, complementing the information offered by the conventional sperm analysis.
ObsEva (Geneva, Switzerland) is advancing a pipeline of orally administered, clinical-stage innovative compounds to treat women’s reproductive health conditions.
Herbio (Tokyo, Japan) has developed a soon-to-be-launched wearable device called Picot that measures basal body temperature.